News Releases

Synlogic Receives Fast Track Designation in U.S. for Lead Candidate, SYNB1020

Synlogic™ Doses First Subject in Phase 1 Trial of Novel Class of Synthetic Biotic™ Medicines

Synlogic Meets First Discovery Milestone in Partnership with AbbVie

Synlogic to Present at Jefferies 2017 Global Healthcare Conference

Synlogic and Mirna Investor Conference Call Replay

Synlogic and Mirna Investor Conference Call Information

Synlogic and Mirna Therapeutics Agree to Merger

Synlogic to Present at 2017 American College of Medical Genetics and Genomics Annual Meeting

Synlogic Appoints COO and Head of Corporate Development

Synlogic Secures Patent on Proprietary Synthetic Probiotic Bacteria for the Treatment of Hyperammonemia

Synlogic Expands Leadership Team to Support Rapid Advancement of the First Synthetic Biotic Towards the Clinic

Synlogic Proprietary Synthetic Biotic Receives FDA Orphan Drug Designation

Synlogic Therapeutics